Ágnes Proszenyák

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Zoltán Szlávik, Márton Csékei, Attila Paczal et al. · Journal of Medicinal Chemistry · 2020 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Screening of Agelasine D and Analogs for Inhibitory Activity against Pathogenic Protozoa; Identification of Hits for Visceral Leishmaniasis and Chagas Disease

Anders Vik, Ágnes Proszenyák, M Vermeersch et al. · Molecules · 2009 · 55 citations · Full text

Veterinary Medicine, Medicinal Chemistry, Pharmacology +17

Oxamides as novel NR2B selective NMDA receptor antagonists

G. BARTA‐SZALAI, István Borza, Éva Bozó et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 45 citations · Full text

Medicine, Neuroscience, Pharmacology +7

Synthesis, Antimicrobial and Antineoplastic Activities for Agelasine and Agelasimine Analogs with a β‐Cyclocitral Derived Substituent

Ágnes Proszenyák, Colin Charnock, Erik Hedner et al. · Archiv der Pharmazie · 2007 · 34 citations

Medicine, Medicinal Chemistry, Pharmacology +16